Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 82

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 82
---
 ESPP. The 2013 ESPP provides participating employees with the opportunity 

13

to purchase up to an aggregate of 2,363,636 shares of our common stock. As of March 31, 2025, we had 1,531,142 shares of common stock available for future issuance under the 2013 ESPP.Stock-based compensation expenseStock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:Three Months EndedMarch 31,(In thousands)20252024Stock options$4,400 $4,071 Restricted stock units6,684 4,966 Employee stock purchase plan275 197 Total stock-based compensation expense$11,359 $9,234 Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:Three Months EndedMarch 31,(In thousands)20252024Research and development expense$4,604 $3,775 Selling, general and administrative expense6,755 5,459 Total stock-based compensation expense$11,359 $9,234 

10. Loss per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs and PSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March 31, 2025 are not considered to be common stock equivalents.We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss for all periods presented, no dilutive effect has been recognized in the calculation of loss per share. Basic